Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
1(11%)
Results Posted
20%(1 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_1
4
44%
Ph phase_2
5
56%

Phase Distribution

4

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(5)
Terminated(3)

Detailed Status

Completed5
Terminated2
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
71.4%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (44.4%)
Phase 25 (55.6%)

Trials by Status

completed556%
recruiting111%
terminated222%
withdrawn111%

Recent Activity

1 active trials
Showing 5 of 9
recruitingphase_2

Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma

NCT03762395
terminatedphase_2

Oral CXA-10 in Pulmonary Arterial Hypertension

NCT04125745
terminatedphase_2

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
completedphase_2

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT03422510
withdrawnphase_2

Anti-Inflammatory Lipid Mediators in Asthma

NCT03680976
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03762395Phase 2

Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma

Recruiting
NCT04125745Phase 2

Oral CXA-10 in Pulmonary Arterial Hypertension

Terminated
NCT04053543Phase 2

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

Terminated
NCT03422510Phase 2

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Completed
NCT03680976Phase 2

Anti-Inflammatory Lipid Mediators in Asthma

Withdrawn
NCT02248051Phase 1

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

Completed
NCT02547402Phase 1

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males

Completed
NCT02460146Phase 1

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

Completed
NCT02313064Phase 1

Oral CXA-10 Study in Healthy Volunteers

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9